

S. Ilinuma et al
U.S.S.N. 09/576,290
Page 4

SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65 or SEQ ID NO:66.

25. (amended) The isolated labeled polypeptide as claimed in claim 24, which comprises the amino acid sequence represented by SEQ ID NO:61 or SEQ ID NO:64, and C-terminus of the polypeptide is amidated.

C⁶ 26. (amended) The isolated labeled polypeptide which comprises the amino acid sequence represented by SEQ ID NO:61 or SEQ ID NO:64, and the C-terminus of the polypeptide is amidated and labeled with [¹²⁵I].

27. (amended) The isolated polypeptide which comprises an amino acid sequence represented by SEQ ID NO:61 or SEQ ID NO:64, wherein the C-terminus of the polypeptide is amidated.

REMARKS

The Applicants appreciate the Examiner's thorough examination of the subject application and request reconsideration of the subject application based on the following remarks.

Claims 21-27 have been amended. No new matter has been added by the claim amendments. Support for the amendment to claim 21-27 can be found throughout the specification as originally filed.

Claim 26 has been amended to correct the typographical error objected to by the Examiner. Applicants respectfully request that the objection be withdrawn.

S. Hinuma et al
U.S.S.N. 09/576,290
Page 5

Claims 21, 22, and 24-27 stand rejected under 35 U.S.C. §101 as being directed to non-statutory subject matter. The Examiner takes the position that labeled and/or amidated polypeptides occur in nature such that the claims allegedly read on polypeptides that occur in nature.

The rejection is respectfully traversed.

Although Applicants respectfully disagree with the rejection, it is believed that the claims as presently amended obviate the rejection.

The Office further states that the application does not fully comply with the sequence rules, 37 C.F.R. §1.821 - 1.825, because the specification does not identify the appropriate sequence identifiers at each place where a sequence is discussed. It also is noted with respect to figures which disclose both an amino acid and a nucleotide sequence, that separate identifiers are required for both the amino acid and the nucleotide sequences.

Applicants have amended the specification, including the brief description of the drawings, to recite sequence identifiers where appropriate which are consistent with the sequence identifiers provided in the sequence listing originally filed in the application. Early consideration and allowance of the application are earnestly solicited.

NON-STATUTORY DOUBLE PATENTING REJECTIONS

Claims 21-27 stand rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable over 1-3 and 9 of U.S. Patent No. 6,558,984. The Examiner further provided the reasoning why there was no statutory bar against this double patenting rejection.

S. Hinuma et al
U.S.S.N. 09/576,290
Page 6


Enclosed herewith is a terminal disclaimer by a registered attorney of record that is compliance with 37 C.F.R. 1.321(b) and 1.321 (c). The enclosed also indicates that the assignee of record commonly owns both the identified patent and subject patent application. Because a timely filed terminal disclaimer executed by an attorney or agent of record overcomes an actual rejection based on a non-statutory double patenting, it is respectfully submitted that the rejection has been overcome and the above identified claims are allowable.

It is respectfully submitted that the subject application is in condition for allowance. Early and favorable action is requested.

Applicants believe that additional fees are not required for consideration of the within Response. However, if for any reason a fee is required, a fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. 04-1105.

Respectfully submitted,

March 12, 2002


John B. Alexander (Reg. No.: 48,399)

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Tel. (617) 439-4444
192887

S. Hinuma et al
U.S.S.N. 09/576,290
Page 7

VERSION WITH CHANGES MARKED

(Additions are underlined; deletions are bracketed.)

IN THE SPECIFICATION

Kindly amend the paragraph starting on page 12, line 2, as follows:

Fig. 1 [SEQ ID NOS: 125-126] shows the nucleotide sequence of the human pituitary-derived G protein-coupled receptor protein cDNA fragment harbored in cDNA clone p19P2 isolated by PCR using human pituitary-derived cDNA and the amino acid encoded by the nucleotide sequence. The primer used for sequencing was -21M13. The underscored region correspond to the synthetic primer.

Kindly amend the paragraph starting on page 12, line 9, as follows:

Fig. 2 [SEQ ID NOS: 127-128] shows the nucleotide sequence of the human pituitary-derived G protein-coupled receptor protein cDNA fragment harbored in cDNA clone p19P2 isolated by PCR using human pituitary-derived cDNA and the amino acid encoded thereby. The primer used for sequencing was M13RV-N (Takara). The underscored region correspond to the synthetic primer.

Kindly amend the paragraph starting on page 12, line 26, as follows:

Fig. 5 [SEQ ID NOS: 129-130] is a diagram comparing the partial amino acid sequence of the protein encoded by the human pituitary-derived G protein-coupled receptor protein cDNA fragment harbored in p19P3 as shown in Figs. 1 and 2 with the known G protein-coupled receptor protein S12863. The shadowed region represents the region of agreement. The 1 to 9 amino acid sequence of p19P2 corresponds to the 1 to 99 amino acid sequence of Fig. 1 and the 156 to 230 amino acid sequence corresponds to the 1 to 68 amino acid sequence of Fig. 2.

S. Hinuma et al
U.S.S.N. 09/576,290
Page 8

Kindly amend the paragraph starting on page 20, line 33, as follows:

Fig. 33 [SEQ ID NOS: 131-133] shows the amino acid sequence of bovine ligand polypeptide and the nucleotide sequences of DNAs coding for bovine polypeptide and rat polypeptide. The arrowmark indicates the region corresponding to the synthetic primer.

Kindly amend the paragraph starting on page 21, line 2, as follows:

Fig. 34 [SEQ ID NOS: 134-135] shows the full-length amino acid sequence and the sequence of cDNA coding for the full coding region of human ligand polypeptide.

Kindly amend the paragraph starting on page 21, line 5, as follows:

Fig. 35 [SEQ ID NOS: 136-138] shows a comparison of the amino acid sequences in the translation region of bovine ligand polypeptide, rat ligand polypeptide, and human ligand polypeptide.

Kindly amend the paragraph starting on page 21, line 5, as follows:

Fig. 52 [SEQ ID NOS: 139-140] shows the sequence of cDNA coding for UHR-1, which is constructed on pAKKO-UHR1-7.

IN THE CLAIMS

Kindly amend claims 21, 22, 24, and 25-27 as follows:

21. (amended) An isolated [A] labeled polypeptide which comprises an amino acid sequence represented by SEQ ID NO:73 or its amide or ester, or a salt thereof.

S. Hinuma et al
U.S.S.N. 09/576,290
Page 9

22. (amended) The isolated labeled polypeptide or its amide or ester, or a salt thereof, as claimed in claim 21, which is labeled with [^3H], [^{125}I], [^{14}C] or [^{35}S].

23. (amended) The isolated labeled polypeptide or its amide or ester, or a salt thereof, as claimed in claim 21, which is labeled with [^{125}I].

24. (amended) The isolated labeled polypeptide as claimed in claim 21, which comprises the amino acid sequence represented by SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65 or SEQ ID NO:66.

25. (amended) The isolated labeled polypeptide as claimed in claim 24, which comprises the amino acid sequence represented by SEQ ID NO:61 or SEQ ID NO:64, and C-terminus of the polypeptide is amidated.

26. (amended) The isolated labeled polypeptide which comprises the amino acid sequence represented by SEQ ID NO:61 or SEQ ID NO:64, and the C-terminus of the polypeptide is amidated and labeled with [^{125}I] [^{125}I].

27. (amended) The isolated polypeptide which comprises an amino acid sequence represented by SEQ ID NO:61 or SEQ ID NO:64, wherein the C-terminus of the polypeptide is amidated.